CENTRAL RATE CONTRACT NO. -144€¦ · E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 144 EFFECTIVE FROM 03.05.2018 TO 02.05.2020. Sir I Madam, Please find enclosed a copy of the

ESIC CENTRAL RATE CONTRACT NO. -144

FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 3rd MAY, 2018 to 2nd MAY, 2020)

DRUGS FOR ANTI CANCER DRUGS AND IMMUNOSUPPRESANT VACCINE

~--L STRICTLy FOR OFFICIAL USE

EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN

C.I.G. ROAD, NEW DELHI - 110 002

ESIC CENTRAL RATE CONTRACT NO. -144

FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020)

DRUGS FOR ANTI CANCER DRUGS AND IMMUNOSUPPRESANT VACCINE

STRICTLY FOR OFFICIAL USE

PUBLISHED BY

DIRECTOR GENERAL EMPLOYEES' STATE INSURANCE CORPORATION

ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI-110 002

Sno. Contents Page No.

1. Forwarding letter along with terms & I-XI conditions for operation of Rate Contract No. 139 (A).

2. List of Approved Pharmaceutical firms. 1

3. Address with Terms & Conditions of the 1-8

Eligible firms

,---4. Index 1-4

5. Rate Schedule 1-23

REGISTERED STRICTLY FOR OFFICIAL USE ONLY

HQRS. OFFICE EMPLOYEES' STATE INSURANCE CORPORATION

PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI -110 002 TeiFax: 011-23234334, E-mail: [email protected], [email protected]

(An IS0-9001 :2008 Certified)

No.U-25/12/142/2017-Med. V/RC 144 Dated: 3rd May, 2018

From:

To

The Director General, E.S.I. Corporation, Panchdeep Bhawan, C.I.G Road, NEW DELHI- 110 002.

The Director, ESI Scheme -All States Medical Superintendent- ESIC Model Hospitals

Sub PURCHASE OF DRUGS AND DRESSINGS UNDER THE E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 144 EFFECTIVE FROM 03.05.2018 TO 02.05.2020.

Sir I Madam,

Please find enclosed a copy of the DG-ESIC Centralised Rate Contract finalised for supply of drugs and dressings under the ESI Scheme in the country. The rate contract will come into force with effect from the date of issue of this rate schedule, i.e, 03.05.2018. Further, the following instructions are issued to govern operation of the Rate Contract.

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers (Director/Add!. Director/Jt. Director/Dy. Director/Administrative Medical Officer/Director (Medical) Delhi shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them. In case the rates of the firms approved in this Rate Contract are found to be higher than their rates in any local Rate Contract or in the market, the same may be intimated along with the documentary proof.

3. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.

4. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

SUPPLIES

5. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase order through email followed by Registered AD post directly to the firm alongwith a copy to the office of the firm situated at the respective zone.

6. It will be ensured before placing order by the Director Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.

7. Supply orders will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.

8. Supply orders will be placed by Heads of ESI Scheme of various States/ Medical Superintendents, ESIC Model Hospitals, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and I or wherever specifically provided in the terms & conditions of the Rate Contract. The

II

Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (000) to operate this Rate Contract.

9. Supply orders against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.

10. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the contractor I seller to supply the item as per the specifications of the relevant rate contract.

11. During transit pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.

12. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.

14. Marking : Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of the each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

TIT

15. Packing : a) It should be ensured that all labels of cartons, ampoules, vials,

bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any consignment without such stamping will not be considered valid and will be rejected.

b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.

c) Supplies to be made in proper boxes. d) Liquid orals to be supplied only in glass/ plastic bottles conforming to

IP I Drugs & Cosmetics Act. e) Large volume parenterals to be quoted and supplied only in plastic

bottles I polypacks conforming to I.P. f) It should be ensured that only first use packaging material of

uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract.

g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.

h) Packing should be able to prevent damage or deterioration during transit.

i) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents.

j) It should be ensured that lSI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has lSI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards.

16. Life Period : a) For Drugs having shelf life of Two years or less: Drug supplied

should not be older than one fourth (1/4) of its shelf life from the date of manufacture.

b) For Drugs having shelf life more than Two years: Drug supplied should not be older than one sixth (1/6) of its shelf life from the date of manufacture.

c) For Imported Drugs: All Imported Drugs should have 50 % of shelf life from the date of manufacture at the time of supply.

17. Pharmacopoeia Specifications : Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the drug supplied as per the provisions of Drug and Cosmetics Act.

IV

18. Testing of Drugs - Quality Control a) Approved Rate Contract Holder should submit a Test Report

that particular batch of medicines tested by the Government/ Government approved Laboratories (as per list circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each supply.

b) The Chief D.D.Os may get at least 10% of the drugs tested in the Government Laboratory, or in any of the Govt. Approved laboratories, the list of which has been issued. Instructions issued in this regard Hqrs. Office from time to time may please be adhered to Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.

c) Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ firm at regular interval to maintain and ensure the quality of drugs.

d) The report of the Govt./Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory.

e) If any store/stores supplied against this Rate Contract are found to be Not of standard quality on test analysis from approved laboratory and I or on inspection by competent authority, the contractor will be liable to replace the entire quantity or make full payment of entire consignment against the

v

particular invoice irrespective of fact that part or whole of the supplied stores may have been consumed.

f) If the product is found to be 'not of standard quality', the cost of testing will be recovered from the supplier.

The classification of defects into different categories is as .Qer .itl..§ guidelines issued by the Drug Controller of India & action will be taken .!2y_J;_SIC for each category of defects. described as under:-

A. CATEGORY 'A' DEFECT (Spurious I Adulterated Drugs)-lf any item I Batch of the item declared Not of Standard quality (NSQ) under Category A . • Recall of the NSQ item immediately from all ESIC/ ESIS User

Units. Recoveries to be initiated by the DDO's wherever payment had been made already.

• Forfeiture of Performance Security from the respective DGESIC Rate Contract.

• Debarring of the Rate Contract holder I Pharmaceutical firm from current and all future DGESIC Rate Contract for a period of five (5) years.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising

due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs) I. If single item/ Batch of item is declared NSQ under Category B

• Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already.


• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate

contract.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of

VI

any adverse reaction reported in the Hospital during administration of the drugs.

II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category B within a year • Recall of the NSQ item immediately from all ESIC/ ESIS User

Units. Recoveries to be initiated by the DDO's wherever payment had been made already.


• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.

• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C CATEGORY' C' DEFECT (Minor Defects) I. If single item/ Batch of item is declared NSQ under Category C





VII

II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category C within a year




• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years


19. Delivery Period- Risk Purchase a. Delivery period will be six weeks. b. If the pharmaceutical firm fails to execute the supply order within

the stipulated period of six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. A pharmaceutical firm can seek extension of the delivery period with the prior consent of the Director Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. That extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

c. If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of pharmaceutical firm. The extra expenditure involved in procuring supplies from elsewhere will, in that case, be recoverable from the

VIII

pharmaceutical firm, in full at discretion of Direct Demanding Officers. The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with firm by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the firm's the Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than five years.

d. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate.

20. Payment a. Payment may be made directly to the firm. Payment for the supply will

be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the pharmaceutical firm to supply the items as per the specifications of the relevant rate contract.

b. The price charged for the stores supplied under the agreement or the rate quoted by firm for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the lowest price at which the firm sells the stores of identical description to any other person(s) during the said period of agreement. If at any time during the said period, the firm reduces the sales price of such stores or sells such stores to any other person at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding Officers and the price payable under the agreement for the stores supplied after the date of its coming in to force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. The preference in the Rate contract will not be changed till any further fresh instructions.

IX

c. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be exclusive of GST Tax but inclusive of all charges for packing and forwarding.

d. GST Taxes, if extra, where legally leviable and intended to be claimed, should be distinctly shown separately alongwith the price quoted. Where this is not done, no claim of GST taxes will be admitted at any later stage and on any ground whatsoever.

e. The purchaser will not pay separately for transit insurance and the firm will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance,octroi etc., if any, will have to be borne by the firm.

f. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that may have occurred during the transit.

21. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters I orders addressed to the contracts.

22. Any payments that have been demanded as per the provision of Clause 22 or under any other clause shall be payable within the time laid down. On failure to do so: -i. The Contractor shall be liable to be debarred for supplying

medicines I drugs etc. to the Corporation for a period not exceeding five years.

ii. The contract is liable to be prosecuted in the court of law. 23. Non Supply

The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report (in Excel format only) along with the comments and details as under:-

PROFORMA FOR NON-SUPPLY REPORT R.C. Item No. & Name of S.O. No. Qty. not Risk Payment Remarks No. Name of firm with supplied Purchase/ if

Drug Date penalty pending levied

1. 2. 3. 4. 5. 6. 7. 8.

X

24. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed. In regard to items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

25. No other document should be entertained for giving any cognizance for placing the supply orders.

26. Acceptance letter issued to the firms by this office cannot be used for placing orders.

Receipt of this letter may please be acknowledged.

Encl.: As above.

Copy to:

Yours faithfully,

~~---(Dr. Akeem Logani)

Dy. Medical Commissioner (RC) For: DIRECTOR GENERAL

1. All Chief Direct Demanding Officers (In-Charge) of ESI Scheme of all States for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.

2. P.S. to Director General for information of Director General. 3. Medical Commissioner I Financial Commissioner for information. 4. Accounts Branch- V (Hqrs. Office) 5. SSMC I SMC (All States)

DY. MEDICA~I~SIONER {RC)

XI

Approved Vendor list

SNO. FIRM NAME

1 ASTRAZENECA PHARMA INDIA LIMITED

2 Baxter (India) Pvt. Ltd.

3 Bayer Zydus Pharma Private Limited

4 Bharat Serums and Vaccines Limited

5 BIOLOGICAL E LIMITED

6 Boehringer lngelheim India Pvt. Ltd.

7 Bristol Myers Squibb India Private Limited

8 Cipla Ltd

9 Dr Reddys Laboratories Limited

10 Eli Lilly and Company (India) Pvt. Ltd.

11 Emcure Pharmaceuticals Limited

12 Gennova Biopharmaceuticals Limited

13 GLEN MARK PHARMACEUTICALS LIMITED

14 I NT AS PHARMACEUTICALS LTD

15 Johnson & Johnson Private Limited

16 Merck Specialities Pvt Ltd

17 Novartis Healthcare Pvt Ltd

18 Panacea Biotec Ltd.

19 PAVIOUR PHARMACEUTICALS PVT. LTD. -

20 Pfizer Products India Private Limited

21 RELIANCE LIFE SCIENCES PVT LTD 1------ -- ·---··-~~-·~-----

22 Roche Products India Pvt Ltd

23 RPG LIFE SCIENCES LTD -24 Sandoz Pvt. ltd.

25 Sanofi Pasteur India Private Limited

26 Sanofi Synthelabo (I) Pvt. Ltd.

27 TROIKAA PHARMACEUTICALS LIMITED

28 USV Private Limited

29 VIRCHOW BIOTECH PRIVATE LIMITED

30 WALLACE PHARMACEUTICALS PVT LTD

Page 1 of 1

Vendor Name

ASTRAZENECA PHARMA INDIA LIMITED

BLOCK N112TH FLOOR MANVATA EMBASSY BUSINESS PARK RACHENAHALLI OUTER RING ROAD BANGALORE- 560045KARNATAKA

Tel: 080-67748000, 67748857, 9811119532

Email: [email protected]

Vendor Name

Baxter (India) Pvt. Ltd.

2nd Floor, Tower C, Building 8, DLF Cyber City, DLF Phase II Gurgaon-122002 Haryana

Tel: 1244500200,8826103999

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4

Delivery within 6{six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis

GST as applicable will be extra except for items where no tax has been approved.

If at any time documents submitted/ information given by the firm in the tender is found to be false/

erroneous, the award will be cancelled.

Supply to be made directly.

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis

GST as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.


Email: [email protected] [email protected]

Vendor Name

Bayer Zydus Pharma Private limited 5th Floor, Bayer House, Central Avenue, Hiranandani Estate, Thane(W)-400607

Tel:222531171~2225455078

9819358800

Term 1

Term 2

Term 3

Term4

Email: chetan.nashirl<[email protected]

Vendor Name

Bharat Serums and Vaccines Limited 3rd Floor, Liberty Towers, Plot No. 10 Kalwa Industrial Estate, Airoli, Navi Mumbai- 400708

Tel: 02245043456, 45043200


Term 1

Term 2

Term 3

Term 4

Page 1 ofS

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.

If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.






Vendor Name

BIOLOGICAL E LIMITED

18/1 & 3 , AZAMABAD HYDERABAD-500020 TELEGANA

Tel: 9312279781

Term 1

Term 2

Term 3

Term 4




Email: [email protected] I [email protected]

Vendor Name

Boehringer lngelheim India Pvt. Ltd.

1102, 11th Floor, Hallmark Business Plaza, Near Guru Nanak Hospital Road, Bandra East, Mumbai- 400051 Maharashtra

Tel: 22-26456477/78, 9999-385171, 9868-439393

Term 1

Term 2

Term 3

Term4





Email: sandeep.l<[email protected] & [email protected]

Vendor Name

Bristol Myers Squibb India Private Limited lndiabulls Finanace Centre, 6th Floor, Tower 1, Senapati Bapat Marg, Elphinstone West Mumbai Maharashtra 400013

Tel: 22 66288600, 66103739, 66103779


Vendor Name

Cipla Ltd

Cipla Limited, Mumbai Central, Mumbai-400008 Maharastra

Tel: 8879967909


Term 1 Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis

Term 2 GST as applicable will be extra except for items where no tax has been approved.

Term 3 If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.

Term 4 Supply to be made directly.





Page 2 of 8

Vendor Name

Dr Reddys Laboratories Limited

7-1-27, Ameerpet-500016, HyderabadTelangana

Tel: 040-49048400

Term 1

Term2

Term 3

Term4

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis G5T as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.

Email: [email protected] & [email protected]

Vendor Name

Eli Lilly and Company (India) Pvt.

Ltd.

Plot No 92, Sector 32 Gurgaon 122001 (Haryana)

Tel: 0124-4753000, 4753012

Term 1

Term 2

Term 3

Term4


If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.

Email: [email protected], [email protected] & [email protected]

Vendor Name

Emcure Pharmaceuticals Limited

Emcure House Plot No. 184, MIDC Bhosari Pune- 411026 Maharashtra

Tel: 2039192761


Vendor Name

Gennova Biopharmaceuticals

Limited

Survey No. 255/2, Phase-1, Rajiv Gandhi IT Park, MIDC, Hinjwadi, Pune-411057 Tel: 020-39821000, 39821020, 8806120606

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term4

Email: [email protected], [email protected]

Page 3 of8

Delivery within 6(six) weeks (ofthe actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.


If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.

Vendor Name

GLENMARK PHARMACEUTICALS

LIMITED GLENMARK HOUSE, B D SAW ANT MARG, Chakala, ANDHERI {EAST) MUMBAI MAHARASHTRA-400099 Tel: 22-40888925/927, 22-40189988, 09324291478

Term 1

Term 2

Term 3

Term 4


Vendor Name

INTAS PHARMACEUTICALS LTD

2nd Floor, B Wing, Corporate Office, Nr. Sola Bridge, Opp. Zydus Hospital, S.G. Highway, Ahmedabad-380054 Tel: 079-26578862


Vendor Name

Johnson & Johnson Private Limited

8th Floor, ARENA SPACE OFF JVLR BEHIND MAJAS DEPOT, JOGESHWARI EAST MUMBAI MAHARASHTRA-400060 Tel: 22 61087103, 022 66718200, 09892101039

Email : [email protected]

Vendor Name

Merck Specialities Pvt Ltd

Godrej One, 8th floor, Pirojshanagar, Eastern Express Highway, Vikroli East, Mumbai 400079 Mumbai Maharashtra Tel: 22 62109000, 22 62109999, 9899002707


Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term4

Page 4 of8

Delivery within 6{six) weeks {ofthe actual date of dispatch) of supply order on FOR Destination basis




Delivery within 6{six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved. If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.

Delivery within 6(six) weeks (ofthe actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.







Vendor Name

Novartis Healthcare Pvt Ltd

201 Palika Bhawan Sector XIII R K Puram New Delhi 110066

Tel: 011-24101308,011-26874021

Term 1

Term 2

Term 3

Term4





Vendor Name

Panacea Biotec ltd.

B-1 Ext./G-3, Mohan Cooperative Industrial Estate, Mathura Road, New Delhi - 110044.

Tel: 011·41679000, 41679090, 9560709313

Term 1

Term 2

Term 3

Term 4






Vendor Name

PAVIOUR PHARMACEUTICALS PVT. LTD.

311-312, Suneja Tower- 1, Distt Centre, Janak Puri New Delhi 110058

Tel: 011 25542181/82/83, 9810075320

Email: [email protected] I [email protected]

Vendor Name

Pfizer Products India Private Limited The Capital, A Wing, 1802/1901, Plot No. C-70, G-Biock, Sandra Kurla Complex Bandra(E)Mumbai Maharashtra 400051

Tel: 022-66932000, 26540274, 9958763337


Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4

PageS of8





Delivery within 6{six) weeks (ofthe actual date of dispatch) of supply order on FOR Destination basis




Vendor Name

RELIANCE LIFE SCIENCES PVT LTD

R-282, TIC AREA OF MIDC, THANE BELAPUR ROAD, RABALE, MUMBAI Navi Mumbai-400701

Tel: 022-40678152, 9899099217


Vendor Name

Roche Products India Pvt Ltd

1503, 15th floor, "The Capital" Bandra Kurla Complex, Sandra East, Mumbai Maharashtra 400051

Tel: 22-33941070/054




Term4 Supply to be made directly.





Email: [email protected] &[email protected]

Vendor Name

RPG LIFE SCIENCES LTD

RPG HOUSE, 463, DR. ANNIE BESANT ROAD, WORLI MUMBAI-400025 MAHARASHTRA

Tel: 0222-4981650 I 67555276, 0222-4970127,9341623989


Vendor Name

Sandoz Pvt. Ltd.

201, Palika Bhawan, Sector-Xiii, R.K.Puram, New Delhi-110066

Tel: 011-24101308, 011-26874021

Term 1

Term2

Term 3

Term 4

Term 1

Term 2

Term 3

Term4

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destinat!on basis







Page 6 of8

Vendor Name

Sanofi Pasteur India Private Limited

Sanofi House, CT 5 No. 117-B, L& T, Business Park, Saki Vihar Road, Powai, Mumbai-110072

Tel: 022-28032000, 28032939


Vendor Name

Sanofi Synthelabo (I) Pvt. Ltd.

Sanofi House, CT S No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai-110072

Tel: 022-28032000, 28032939


Vendor Name

TROIKAA PHARMACEUTICALS LIMITED Commerce House- 1, Satya Marg, Bodakdev, Ahmedabad-380054 Gujarat

Tel: 079-26856242 I 43 I 45 I 46, 9879615617


Vendor Name

USV Private Limited

Arvind Vithhal Gandhi Chowk, B.S.D Marg, Govandi, Mumbai- 400088 Maharashtra Tel: 022-25564048


Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term4

Page 7 of8

















Vendor Name

VIRCHOW BIOTECH PRIVATE LIMITED PLOT N0.319,3rd FLOOR,SWAMY AYYAPPA Co-op HOUSING SOCIETY,MADHAPUR, HYDERABAD TELANGANA

Tel: 4023119481


Vendor Name

WALLACE PHARMACEUTICALS PVT LTD B 307-312 FLORAL DECK, PLAZA. OFF CENTRAL MIDC ROAD, ANDHERI (EAST), MUMBAI MAHARASHTRA400093

Tel: 022-29261152, 022-28390733, 9820360019

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4










Page 8of8

INDEX (RC 144) Page

Sno. Item No. Item Name and Description Unit No.

1 288 CYTOSINE ARABINOSIDE 100mg INJ 1 vial 1

2 459b GEMCITABINE INJ- Each vial to contain: Gemcitabine lgm. 1 vial 1

3 487a PACLITAXEL INJ - Each vial to contain: PaclitaxellOOmg. 1 vial 1

4 600 INFLIXIMAB INJ- Each vial to contain: lnfliximab 100mg. 1 vial 2

5 1406 TEMOZOLOMIDE 250mg TAB/ CAP 1 tab/cap 2

6 1447a DASATINIB TAB- Each tab to contain: Dasatinib 20mg ltab 2

7 1447b DASATINIB TAB- Each tab to contain: Dasatinib 50mg. 1 tab 2

8 1447c DASATINIB TAB- Each tab to contain: Dasatinib 70mg 1 tab 3

9 1454b CAPECITABINE TAB- Each tab: Capecitabine 500mg 1 tab 3

10 1473b SUNITINIB MALATE 25mg TAB/CAP 1 tab/cap 3

11 1475 ANASTROZOLE lmg TAB 1 tab 4

APREPITANT TAB/CAP- Each pack to contain: Aprepitant (125 mg one

12 1641 tab/cap and 80 mg twa tab/cap) 1 tab/cap 4

13 1728 GEFITINIB TAB- Each tab: Gefitinib 250mg ltab 4

14 1732 DECITABINE SOmg INJ 1 vial 5

15 1733 NILOTINIB CAP- Each cap: Nilotinib 150mg 1 cap 5

16 1738 SEVELAMER HCL 800mg TAB ltab 5

17 1803 SEVELAMER HCL 200mg TAB 1 tab 6

18 1812 CETUXIMAB lOOMG INJ- Each ml: Cetuximab 5mg 20m! vial 6

19 1813 CETUXIMAB 500MG INJ- Each ml: Cetuximab 5mg 100m! 6

20 1968 VALGANOCICLOVIR 450mg TAB ltab 6

21 1983 OXALIPLATIN INJ- Each vial: Oxaliplatin 100 mg 1 vial 7

22 1984 PACLITAXEL INJ- Each vial: Paclitaxel260mg 1 vial 7

23 1985 TEMOZOLOMIDE 100mg CAP 1 cap 7 -·

Page 1 of 4

INDEX (RC 144) - Page

Sno. Item No. Item Name and Description Unit No. --

24 1650a FILGRASTIM 150mcg INJ 1 PFS/ vial 8

25 1731 RASBURICASE 1.5mg INJ 1m1Vial 8

26 1804 TACROLIMUS 1MG TAB 1 Tab 8

27 526 GOSERELIN INJ- Each PFS to contain: Goserelin 3.6mg. 1 PFS 9

28 1640 LAPATINIB TAB- Each tab to contain: Lapatinib 250mg 1 tab 9

29 1471 HUMAN ALBUMIN 20% INJ 50 ml bot 9

30 2124 Pazopanib Hydrochloride equivalent to 400mg Pazopanib Tab 1 tab 9

Eltrombopag Olamine equivalent to 25mg of eltrombopag as

31 2125 eltrombopag free acid Tab 1 tab 10

Eltrombopag Olamine equivalent to SOmg of eltrombopag as

32 2126 eltrombopag free acid Tab 1tab 10

33 2127 Ceritinib 150mg Cap 1 cap 10

34 2128 lbrutinib 140mg. Cap/Tab 1 cap/tab 10

35 2129 Ruxolitinib 15mg_ Tab 1 tab 10

36 2130 Ruxolitinib 20mg Tab 1 tab 11

37 2131 Ruxolitinib 5mg Tab 1 tab 11

38 2133 Obinutuzumab 1000 mg lnj. 1 vial 11

39 2134 Nivolumab 40mg (40mg/4 mL) lnj. 1 vial 11

40 2136 Pertuzumab 420mg (30mg/ml) lnj. 1 vial 11

Triptorelin Pamoate (Sterile lypholized) equivalent to Triptorelin

41 2137 11.25mg Pamorelin LA 11.25 lnj. Each Single dose 1 vial 12

42 2138 Crizotinib 250mg Cap 1 cap 12

43 2139 Denosumab 120 mg (70mg/ml) Total filll.7ml in 5ml vial 1 vial 12

44 2140 Panitumumab 100 mg (20mg/ml) Each Single use vial of 5 ml 1 vial 12

45 2141 Carfilzomib 60mg sterile lypholized powder lnj. I vial 13

Page 2 of4

INDEX {RC 144) Page


46 2143 Palbociclib 125mg Cap 1 cap 13

47 2144 Afatinib 20 mg Tab 1 tab 13

48 2145 Afatinib 30 mg Tab 1 tab 13

49 2149 Trastuzumab emtansine 160mg lnj. 1 vial 14

50 2153 Axitinib 5 mg Tab 1 tab 14

51 2154 Trabectedin 1 Mg lnj. 1 vial 14

52 2156 Trastuzumab emtansine 100mg lnj. 1 vial 14

53 2157 Afatinib 40 mg Tab ltab 15

54 2160 Regorafenib 4-0mg Tab 1 tab 15

55 2165 Abiraterone acetate 250 mg Tab ltab 15

Recombinant Human Granulocyte Macrophage Colony stimulatingFactor

56 2167 (r-hu-GMCSF) 500microgram lnj. 1 inj 15

57 2174 Erlotinib 150 MG Tab ltab 16

58 2175 Bendamustine HCL1Dgmg lnj. 1 vial 16 ....

59 2178 Everolimus 05 mg Tab ltab 16

Ramucirumab Concentrate for Solution for Infusion Each vial contains:

Ramucirumab SOOmg I SOml vial component :Ramucirumab 500mgl-

Histidine 32.5mgl-Histidine Monohydrochloride 61.0mg Glycine

499mgSodium Chloride 219mgPolysorbate -80 5.0mg Water for Injection

60 2179 q.s SOmlvial 17

Secukinumab 150mg Sucrose 92.43mg l- Histidine I l- Histidine MCL

61 2180 Monohydrate 4.656 mg Polysorbate 80- 0.60mg. II:JOIImumao (r-UNA ongu1TTacn smg1e use pre-~111ea ~ynnge contians:

1 vial 17

62 2181 Golimumab 50mgl0.5ml Component [amount per dose (mg)]: 1 PFS 17

63 490 MYCOPHENOLATE MOFETIL 500mg TAB 1 tab 18

64 1708 TACROLIMUS OINT- Each tube to contain: Tacrolimus 0.03%: lOgm 18

65 1709 TACROLIMUS OINT- Each tube to contain: Tacrolimus 0.1% lOgm 19 . . .

Page 3 of 4

INDEX (RC 144) Page


66 1970 MYCOPHENOLATE 360mg TAB ltab 19

67 1988 TACROLIMUS O.Smg TAB/CAP 1 tab/cap 20

68 1969 MYCOPHENOLATE 180mg TAB 1 tab 20

69 1971 MYCOPHENOLATE 540mg TAB 1 tab 20

70 2183 Heparin Topical Solution 1000 IU/ml 5ml 20

71 1990 SEVELAMER 800mg SACHET 1 sachet 21 LOW CALCIUM CAPO- Each to contain: CAPO Bags with 1.5%

concentration containing 40 mEq/litre of lactate and 2.5 mEq/litre of Ca

72 1455a with asymmetrical Y connector 2Ltr Bag 21

LOW CALCIUM CAPO- Each to contain: CAPO Bags with 2.5%

concentration containing 40 mEq/litre of lactate and 2.5 mEq/litre of Ca

73 1455b with asymmetrical Y connector 2Ltr Bag 21

HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN- Each vial to contain:

74 1339b Human Tetanus Specific Immunoglobulin 500 units. 1 Vial 21

75 1652b HEPATITIS B IMMUNOGLOBULIN 200 IU INJ 1mlvial 22 IMMUNOGLOBULIN- Each to contain: Rho (D) Immune Globulin (Human)

76 1814 1500 IU.(300mcg) 1 inj 22 IMMUNOGLOBULIN- Each 1 ml solution contain: Active substance(s)

Human plasma proteins 50 mg, lgM 6 mg (12%), lgA 6 mg (12%) lgG 38

1---77 1819 mg (76%) 1 vial 22

ANTI RABIES VACCINE- Each ml to contain: HRG (Rabies Immunoglobulin 2m I

78 1919 (Human)) 1501U amp/vial 22

HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN- Each vial to contain:

79 1339a Human Tetanus Specific Immunoglobulin 250units. 1 Vial 23

Meningococcal Group (A,C,Yand W135) Polysachharide Diphtheria

80 2185 Toxoid Conjugate Vaccine 0.5 ml Vial 23

Snake Anti venin (Polyvalent) IP 10m I (Enzyme refined Equine Globulins)

Each 1m I neutralises: 0.60mg of Cobra venom (Naja Naja), 0.45mg of

Common Krait Venom(Bungarus Caeruleus), 0.60mg of Ruseells Viper

Venom (Vipera russelli), 0.45mg of Saw scaled Viper Venom (Echis

81 2186 carinatus) Preservatives PhenoiiP 50.25% w/v 10m I 23

Page 4 of4

Employee.s' State Insurance Corporation

Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 144

Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020

litem No I Drug Description I Packing

Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted

288 CYTOSINE ARABINOSIDE INJ - Each vial to contain: Cytosine 11 vial Arabinoside 100mg.

I NT AS

PHARMACEUTICALS LTD

54/1 vial 1 ml Vial FIRST ARASID-100

SAME AS IN ITEM

Rupees fifty four only

Pfizer Products India 204.65/1 vial 1 vial SECOND CYTOSAR 100MG (Cytarabine) Mfg: Pfizer (Perth) Pty Limited,

Australia

Private Limited

SAME AS IN ITEM

Rupees two hundred four paisa sixty five only

l459b I GEMCITABINE INJ- Each vial to contain: Gemcitabine lgm. !1 vial

Cipla ltd

I NT AS

PHARMACEUTICALS

LTD

900/1 vial I vial FIRST

Rupees nine hundred only

ONCOGEM 1000 SAME AS IN ITEM

1090/1 vial 1 Vial SECOND GEMIBINE 1000

SAME AS IN ITEM

Rupees one thousand ninety only

l487a I PACLITAXEL INJ - Each vial to contain: PaclitaxellOOmg. 11 vial

I NT AS PHARMACEUTICALS

LTD

Cipla Ltd

498/1 vial 16.7 mi. Vial FIRST CYTAX 100

SAME AS IN ITEM

Rupees four hundred ninety eight only

747/1 vial 16.7ML SECOND PACUTAX 100 SAME AS IN ITEM

Rupees seven hundred forty seven only

·Page 1 of23

Employees' State Insurance Corporation




Firm Name Firm Rate/ unit Firm Packing Preference Description of stores

1 Goo IINFLIXIMAB INJ- Each vial to contain: lnfliximab lOOmg.

JOHNSON & 15155.58/1 vial Vial of 100mg FIRST JOHNSON PVT LTD

accepted

11 vial

REMICADE lOOMG Mfg: Cilag AG, Switzerland SAME AS IN ITEM

Rupees fifteen thousand one hundred fifty five paisa fifty eight only

1406 TEMOZOLOMIDE TAB/ CAP - Each tab/cap to contain: 1 tab/cap Temozolomide IP 250mg

Cipla Ltd 420/1 tab/cap 5 cap FIRST

Rupees four hundred twenty only

TEMOSIDE 250 SAME AS IN ITEM

EM CURE PliARMACEUTICALS LIMITED

440/1 tab/cap 5 cap SECOND TEMCURE-250

Rupees four hundred forty only

l1447a I DASATINIB TAB- Each tab to contain: Dasatinib 20mg

BRISTOL MYERS 1102.95/1 tab 60 tab FIRST SQUIBB INDIA PRIVATE LIMITED

SAME AS IN ITEM

11 tab

Sprycel 20mg Mfg: Bristol Myers Squibb Company, Usa SAME AS IN ITEM

Rupees one thousand one hundred two paisa ninety five only

l1447b I DASATINIB TAB- Each tab to contain: Dasatinib SOmg.


11 tab

Sprycel 50mg Mfg:

Bristol-Myers Squibb, S.R.L., Italy SAME AS IN ITEM

Rupees two thousand two hundred six paisa forty five only

Page 2 of 23




lttem No I Drug Description I Packing


l1447c I DASATINIB TAB- Each tab to contain: Dasatinib 70mg 11 tab


Sprycel 70mg Mfg: Bristol-Myers Squibb, S.R.L., Italy SAME AS IN ITEM

Rupees two thousand three hundred sixty paisa sixteen only

l1454b I CAPECITABINE TAB- Each tab to contain: Capecitabine 500mg 11 tab


19.9/1 tab 10 tab FIRST CAPSY 500 TAB

LTD SAME AS IN ITEM

Rupees nineteen paisa ninety only

Cipla Ltd 21/1 tab lOtab SECOND CAPEGARD SOO SAME AS IN ITEM

Roche Products India 93.333/1 tab Pvt Ltd

Rupees twenty one only

One Box of 120 THIRD tab

Rupees ninety three paisa three three three only

Xeloda SOOmg Mfg: F. Hoffmann-La Roche Ltd., Switzerland SAME AS IN ITEM

1473b SUNITINIB MALATE TAB/CAP - Each tab/cap to contain: 1 tab/cap Sunitinib Malate 25mg

Pfizer Products India 3000/1 tab/cap 7 tab FIRST Private Limited

Rupees three thousand only

Page 3 of23

SUTENT 25MG Mfg: Pfizer ltalia S.r.l., Italy SAME AS IN ITEM




[Item No I Drug Description I Packing


11475 I ANASTROZOLE TAB- Each tab to contain Anastrozole 1mg j1 tab

EMCURE PHARMACEUTICALS LIMITED

Cipla Ltd

5.5/1 tab 10 tab FIRST ELINAL-1MG

SAME AS IN ITEM

Rupees five paisa fifty only

12.7/1 tab 10 tab SECOND ARMOTRAZ SAME AS IN ITEM

Rupees twelve paisa seventy only

1641 APREPITANT TAB/CAP- Each pack to contain: Aprepitant (125 1 tab/cap mg one tab/cap and 80 mgtwo tab/cap)

GLEN MARK 707/ltab/cap KIT OT 3TABS. FIRST APRECAP PHARMACEUTICALS LIMITED

SAME AS IN ITEM

Rupees seven hundred seven only

[1728 I GEFITINIB TAB~ Each tab to contain: Gefitinib 250mg l1tab EMCURE PHARMACEUTICALS LIMITED

Cipla Ltd

26.66/1 tab 10 tab FIRS! EMFIB- 250

SAME AS IN ITEM

Rupees twenty six paisa sixty siK only

46.6667/1 tab 30tab SECOND GEFTICIP SAME AS IN ITEM

Rupees forty six paisa six six six seven only

Page 4 of23






11732 I DECITABINE INJ- Each vial to contain: Decitabine a€" 50mg 11 vial Dr Reddys Laboratories Limited

JOHNSON & JOHNSON PVT LTD

2091.S/1 vial 1 FIRST Xalibo

SAME AS IN ITEM

Rupees two thousand ninety one paisa fifty only

298S7.S/1 vial Vial ofSOmg SECOND DACOGEN IV 1 X SOMG Mfg: Janssen Pharmaceutica NV, Belgium SAME AS IN ITEM

Rupees twenty nine thousand eight hundred fifty seven paisa fifty only

11733 I NILOTINIB CAP- Each tap to contain: N:.:ilo:::t""in:.:ib::_:::15"'0:.:m...,g~~---'-l_::1"'c=:ap"------c~---::--:::-----' Novartis Healthcare 1397.85S/1 cap 4 cap FIRST Tasigna 150mg Mfg: Pvt Ltd Novartis Pharma Stein

AG, Switzerland SAME AS IN ITEM

Rupees one thousand three hundred ninety seven paisa eight five five only

1738 SEVELAMER HCL TAB - Each tab to contain: Sevelamer Hcl 1 tab 800mg


USV PRIVATE LIMITED

9.8/1 tab 10tab FIRST FOSEAL- 800

SAME AS IN ITEM

Rupees nine paisa eighty only

12.63/1 tab 10tab SECOND Sevagel 800mg

SAME AS IN ITEM

Rupees twelve paisa sixty three only

Page 5 of 23






1803 SORAFENIB TAB - Each tab to contain: Sorafenib Tosylate 1 tab 200mg.

Cipla Ltd 37.0833/1 tab 120 tab FIRST SORANIB SAME AS IN ITEM

Rupees thirty seven paisa zero eight three three only

Bayer Zydus Pharma 1780.51/1 tab 10tab SECOND Nexavar Mfg: Bayer AG, Germany Private Limited SAME AS IN ITEM

Rupees one thousand seven hundred eighty paisa fifty one only

11812 I CETUXIMAB lOOMG INJ- Each ml to contain: Cetuximab Smg I20ml vial

MERCK SPECIALITIES 15046.13/:!0ml 20ml Vial FIRST ERBITUX Smg/ml Mfg: PVTLTD vial Merck KGaA, Germany

SAME AS IN ITEM

Rupees fifteen thousand forty six paisa thirteen only

11813 I CETUXIMAB SOOMG INJ- Each ml to contain: Cetuximab Smg l100m1

MERCK SPECIALITIES 75230,66/100ml 100m I Vial FIRST ERBITUX Smg/ml Mfg: PVTLTD Merck KGaA, Germany

SAME AS IN ITEM

Rupees seventy five thousahd two hundred thirty paisa sixtY six only

1968 VALGANOCICLOVIR TAB - Each tab to contain:Valganociclovir 1 tab 450mg

Cipla Ltd 126.5/1 tab 4tab FIRST VALGAN SAME AS IN ITEM

Rupees one hundred twenty six paisa fifty only

Roche Products India 461.667/1 tab Pvt Ltd

One bottle of 60 SECOND Valcyte 450mg Mfg: tab Patheon Inc., Canada

SAME AS IN ITEM

Rupees four hundred sixty one paisa six six seven only

Page 6of23


Rate Schedule of Running Rate Contract No. U-2.5/12/142/2017-Med V FOR RC 144


I tt·em No I Drug Description I Packing


[1983 I OXALIPLATIN INJ- Each vial to contain: Oxaliplatin 100 mg l1 vial

Cipla Ltd 900/1 vial 50ML FIRST

Rupees nine hundred only

X-PLAT 100 SAME AS IN ITEM

Dr Reddys 3551.73/1 vial 1 SECOND Dacotin 100 Mfg: laboratories Limited Debiopharm

International SA, Belgium SAME AS IN ITEM

Rupees three thousand five hundred fifty one paisa seventy three only

11984 I PACLITAXEL INJ- Each vial to contain: Paclitaxel 260mg 11 vial

I NT AS

PHARMACEUTICALS lTD

Cipla Ltd

1290/1 vial 43.4 ml Vial FIRST CYTAX260

SAME AS IN ITEM

RUpees one thousand two hundred ninety only

1800/1 vial 43.4ML SECOND PACLITAX 260 SAME AS IN ITEM

Rupees one thousand eight hundred only

1985 TEMOZOLOMIDE CAP - Each cap to contains : Temozolomide 1 cap 100mg


Cipla Ltd

80/1 cap

180/1 cap

5 cap

Rupees eighty only

5 cap

FIRST TEMCURE-100

SAME AS IN ITEM

SECOND TEMOSIDE 100 SAME AS IN ITEM

Rupees one hundred eighty only

Page 7 of 23






lt650a I FILGRASTIM INJ- Each PFS/Vial to contain: Filgrastim 150 meg It PFS/ vial

I NT AS 495/1 PFS/ vial 1 ml PFS FIRST NEUKINE 150 meg PFS

PHARMACEUTICALS

LTD

Rupees four hundred ninety five only

lt731 I RASBURICASE INJ- Each vial to contain: Rasburicase 1.5 mg

VIRCHOW BIOTECH 5760/1ml Vial VIAL FIRST

PRIVATE LIMITED

Rupees five thousand seven hundred sixty only

[1804 I TACROLIMUS lMG TAB" Each Tab to contain: Tacrolimus lmg

I NT AS

PHARMACEUTICALS

LTD

8.98/1 Tab 10 cap FIRST

Rupees eight paisa ninety eight only

SAME AS IN ITEM

ltmiVial

INJ.TULY

SAME AS IN ITEM

11 Tab TAKFA 1 CAP

SAME AS IN ITEM

RPG LIFE SCIENCES

LTD 12.4/1 Tab 10cap SECOND lmunotac 1mg

Panacea Biotec Ltd. 12.9/1 Tab

SAME AS IN ITEM

Rupees twelve paisa forty only

10 cap THIRD Pangraf 1.0 SAME AS IN ITEM

Rupees twelve paisa ninety only

Page 8 of 23 ··~






I 526 I GOSERELIN INJ -Each PFS to contain: Goserelin 3.6mg.

ASTRAZENECA 3642.67/1 PFS PFS FIRST PHARMA INDIA

LIMITED

accepted

11 PFS ZOLADEX 3.6MG

Mfg: AstraZeneca UK

Limited, United Kingdom SAME AS IN ITEM

Rupees three thousand six hundred forty two paisa sixty seven only

11640 I LAPATINIB TAB- Each tab to contain: Lapatinib 250mg

Novartis Healthcare 339/1 tab Bottle of 30 tab FIRST

Pvt Ltd

Rupees three hundred thirty nine only

11 tab Tykerb 2SOmg Mfg:

Glaxo Operations UK Ltd.,

UK SAME AS IN ITEM

11m HUMAN ALBUMIN 20% INJ - Each bot to contain: Human 50 ml bot L_ Albumin 20%

PAV:c-:IO::::Uc=R:---L..:..:=.::.:--_-""2__.9~35:.06/50 ml

PHARMACEUTICALS

PVT. LTD

bot

SOMLBOTTLE FIRSi ALBIOMIN 20 PERCENi

SOML Mfg: Biotest

Pharma GmbH, Germany SAME AS IN ITEM

Rupees two thousand nine hundred thirty five. paisa six only

2124 Each film coated tablet to contains Pazopanib Hydrochloride equivalent to 400mg Pazopanib

Novartis Healthcare 347/l tab Bottle of 30 tab I'IRST

Pvt Ltd

Rupees three hundred forty seven only

·Page 9 of 23

1 tab

Votrient 400mg Mfg: Glaxo Operations UK Ltd.,

UK SAME AS IN ITEM



Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020



2125 Each film coated tablet to contains:Eitrombopag Olamine 11 tab equivalent to 25mg of eltrombopag as eltrombopag free acid

Novartis Healthcare 730/1 tab Box of 2X7tab FIRST Revolade 25mg Mfg: Pvt ltd Glaxo Operations UK Ltd.,

LIK

Rupees seven hundred thirty only

2126 Each film coated tablet to contains:Eitrombopag Olamine equivalent to SOmg of eltrombopag as eltrombopag free acid

Novartis Healthcare 1460/1 tab Box of 2X7tab FIRST Pvt Ltd

Rupees one thousand four hundred sixty only

I 2127 . -~ Each hard gelatin capsule to contains: Ceritinib 150mg

Sandoz Pvt. Ltd. 546.8134/1 cap Multipack: 150 FIRST (3 packs of SO) cap

SAME AS IN ITEM

1 tab

Revolade SOmg Mfg: Glaxo Operations UK Ltd., UK SAME AS IN ITEM

11 cap Spexib Mfg: Novartis Pharma Stein AG, Switzerland SAME AS IN ITEM

Rupees five hundred forty six paisa eight one three four only

I 2128 I Each cap/tab to contain: lbrutinib 140mg.

JOHNSON & 1573.125/1 Bottle of 90 Cap FIRST JOHNSON PVT LTD cap/tab

I 1 cap/tab

IMBRUVICA Mfg: Pharmacyclics, Inc., USA SAME AS IN ITEM

Rupees one thousand five hundred seventy three paisa one two five only

I 2129 I Each tablet to contains Ruxolitinib 15mg

Novartis Healthcare 2735/1 tab 14 tab I'IRST Pvt ltd

11 tab Jakavi.lSmg Mfg: Novartis Pharma Stein AG, Switzerland SAME AS IN ITEM

Rupees two thousand seven hundred thirty five only

Page 10 of23

Employees' State ln.surance Corporation





I 2130 I Each tablet contains Ruxolitinib 20mg Novartis Healthcare 2735/1 tab 14 tab FIRST Pvt Ltd

accepted

[1 tab Jakavi 20mg Mfg: Novartis Pharma Stein AG, Switzerland SAME AS IN ITEM

Rupees two thousand seven hundred thirty five only

I 2131 I Each tablet contains Ruxolitinib Smg Novartis Healthcare 1365/1 tab 14 tab FIRST Pvt Ltd

[1 tab Jakavi 5mg Mfg: Novartis Pharma Stein AG, Switzerland SAME AS IN ITEM

Rupees one thousand three hundred sixty five only

[21)3 I Eac-h-vial to contains; Obinutuzumab 1000 mg Roche Products India 256021/1 vial 1 vial Pvt Ltd

FIRST [1 vial

Gazyva 1000mg Mfg: F. Hoffmann-La Roche Ltd., Switzerland SAME AS IN ITEM

Rupees two lacs fifty six thousand twenty one only

I 2134 I Each 4 ml vial to contains: Nivolumab40mg (40mg/4ml) BRISTOL MYERS 32676.S2/1 vial 1 Vial FIRST SQUIBB INDIA PRIVATE LIMITED

[lvial Opdyta 40mg Mfg: Bristol-Myers Squibb Holdings Pharma Ltd., USA SAME AS IN ITEM

Rupees thirty two thousand six hundred seventy six paisa fifty two only

I 2136 I Each 14m I vial to contain : Pertuzumab 420mg (30mg/ml) Roche Products India 169330/111ial 1 vial FIRST Pvt Ltd

11 vial Perjeta 420mg Mfg: F. Hoffmann-La Roche ltd.,

Switzerland SAME AS IN ITEM

Rupees one lac sixty nine thousand three hundred thirty only

Page 11 of23


Rate Schedule of Running Rate Contract No. U-25/12/14.2/2017-Med V FOR RC 144

Valid from Thursday May 3'd 2018 to Saturday May znd 2020

[ttem No I Drug Description

Firm Name Firm Rate/ unit Firm Packing Preference

2137 Each Single dose vial contains:(Sterile lypholized) Triptorelin Pamoate equivalent to Triptorelin 11.25mg Pamorelin LA 11.25 lnj.

Dr Reddys 10850/1 vial 1 Vial FIRST Laboratories Limited

Rupees ten thousand eight hundred fifty only

I Packing

Description of stores accepted

1 vial

Pamorelin LA 11.25 Mfg: Debiopharm Research & Manufacturing SA, Switzerland SAME AS IN ITEM

2138 Crizotinib Capsules Each Hard Geletin Cap. contains: Crizotinib 1 cap 250mg

Pfizer Products India 1165.29/1 cap 6 xlO cap Private Limited

FIRST CRIZALK 250MG Mfg: Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg, Germany SAME AS IN ITEM

Rupees one thousand one hundred sixty five paisa twenty nine only

2139 Each vial to contains Denosumab 120 mg (70mg(ml) Total fill 1.7ml in Sml vial


20S62.14/1 vial 1 FIRST

1 vial

Xgeva 120 Mfg: Amgen Manufacturing Limited, USA SAME AS IN ITEM

Rupees twenty thousand five hundred sixty two paisa fourteen only

2140 Each Single use vial of 5 ml contains Panitumumab 100 mg 11 vial (20mg/ml)


27900/1 vial 1 FIRST Vettibix 100 Mfg:

Rupees twenty seven thousand nine hundred only

Page 12 of 23

Amgen Manufacturing Limited, USA SAME AS IN ITEM

I



Valid from Thursday May 3'"d 2018 to Saturday May 2"d 2020

lttemNo I Drug Description I Packing


2141 Each vial to contains: Carfilzomib 60mg sterile lypholized I vial powder


33000/1 vial 1 FIRST

Rupees thirty three thousand only

2143 Palbociclib Capsules Each Palbociclib 125mg

Pfizer Products India 3231.29/1 cap Private Limited

hard gelatin cap contains

21 cap per bott FIRST

Kyprolis 60 lnj Mfg: Amgen Inc. USA at Amgen Manufacuring Limited, USA SAME AS IN ITEM

: 11 cap

PALBACE 125MG Mfg: Pfizer Pharmaceutical LLC, USA SAME AS IN ITEM

Rupees three thousand two hundred thirty one paisa twenty nine only

I 2144 I Each tab to contains: Afatinib 20 mg

Boehringer lngelheim 1470.48/1 tab 7 tab FIRST India Pvt. Ltd.

11 tab Xovoltib 20mg Mfg: Boehringer lngelheim Pharma GmbH & Co., Germany SAME AS IN ITEM

Rupees one thousand four hundred seventy paisa forty eight only

I 2145 I Each tab to contains: Afatinib 30 mg

Boehringer lngelheim 1516.87/1 tab 7 tab FIRST India Pvt. Ltd.

11 tab Xovoltib 30mg Mfg: Boehringer lngelheim Pharma GmbH & Co., Germany SAME AS IN ITEM

Rupees one thousand five hundred sixteen paisa eighty seven only

Page 13 of23


Rate Schedule of Running Rate Contract No. U-25/12/3.42/2017-Med V FOR RC 144




I 2149 I Each vial to contains: Trastuzumab emtansine 160mg

Roche Products India 169080/1 vial 1 vial FIRST Pvt Ltd

Rupees one lac sixty nine thousand eighty only

I 2153 I Each film coated tab to contains: Axitinib 5 mg

Pfizer Products India 2044.19/1 tab 2 strips of 14 FIRST Private Limited tab

accepted

11 vial

Kadcyla 160mg Mfg: F. Hoffmann-La Roche Ltd., Switzerland SAME AS IN ITEM

11 tab

INLYTA SMG Mfg: Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg, Germany SAME AS IN ITEM

Rupees two thousand forty four paisa nineteen only

1 2154 I Each vial to contains:Trabectedln 1 illlg JOHNSON& 49638.75/1 vial 1 vial JOHNSON PVT LTD

FIRST 11 vial

YONOELIS 1 X 1MG Mfg: Janssen Pharmaceutica NV, Belgium SAME AS IN ITEM

Rupees forty nine thousand six hundred thirty eight paisa seventy five only

I 2156 I Each vial to contains: Trastuzumab emtansine 100mg

Roche Products India 105680/1 vial 1 vial FIRST Pvt Ltd

11 vial

Kadcyla 100mg Mfg: F. Hoffmann-La Roche Ltd., Switzerland SAME AS IN ITEM

Rupees one lac five thousand six hundred eighty only

Page 14 of23






I 2157 I Each tab to contains: Afatinib 40 mg 11 tab

Boehringer lngelheim 1549.08/1 tab 7 tab FIRST Xovoltib 40mg Mfg: India Pvt. Ltd. Boehringer lngelheim

Pl)arma GmbH & Co., Germany SAME AS IN ITEM

Rupees one thousand five hundred forty nine paisa eight only

I 2160 I Each Tab to contains:Regorafenib 40mg 11 tab

Bayer Zydus Pharma 756.3/1 tab Bottle of 28 tab FIRST Nublexa Mfg: Bayer Private Limited

Rupees seven hundred fifty six paisa thirty only

AG,Germany SAME AS IN ITEM

[f165 I Each tab to contain: Abiraterone acetate 250 mg l1 tab

Cipla Ltd


62.0833/1 tab 120 tab FIRST ZECYTE SAME AS IN ITEM

Rupees sixty two paisa zero eight three three only

699.789/1 tab Bottle of 120 tab

SECOND ZYliGA 250MG Mfg: Janssen-Cilag SpA, Italy SAME AS IN ITEM

Rupees six hundred ninety nine paisa seven eight nine only

2167 lnj Recombinant Human Granulocyte Macrophage Colony 1 inj stimulatingFactor (r-hu-GMCSF) SOOnHcrogram

Gennova 1320/1 inj 1Vial FIRST EMGRAST-M 500MCG Biopharmaceuticals Limited

SAME AS IN ITEM

Rupees one thousand three hundred twenty only

Page 15 of 23




[Item No I Drug Description

Firm Name Firm Rate/ unit Firm Packing

[2174 [ Each tab to contain:Erlotinib 150 MG

Cipla Ltd 59/ltab 30tab

Rupees fifty nine only

Roche Products India 1520/1 tab Pvt Ltd

One boxof30 tab

I Packing

Preference Description of stores accepted

[1 tab

FIRST ERLOCIP 150 SAME AS IN ITEM

SECOND Tarceva 150mg Mfg: F. Hoffmann-La Roche Ltd., Switzerland SAME AS IN ITEM

Rupees one thousand five hundred twenty only

[ 2175 [ Each vial to contains: Bendamustine HCL lOOmg JOHNSON & 4105.31/1 vial 1 vial FIRST JOHNSON PVT LTD

[1 vial

RIBOMUSTIN lOOMG Mfg: Oncotec Pharma Produktion GmbH, Germany SAME AS IN ITEM

Rupees four thousand one hundred five paisa thirty one only

[2178 I Each Tab to contains: EverolfmusOS mg [1 tab Dr Reddys 400/1 tab 10 tab FIRST Volantis 5 mg Laboratories Limited

SAME AS IN ITEM

Rupees four hundred only

Novartis Healthcare 879/1 tab 10tab SECOND Afinitor 5mg Mfg: Pvt Ltd

Rupees eight hundred seventy nine only

Page 16 of23

Novartis Pharma Stein AG, Switzerland SAME AS IN ITEM




lttem No I Drug Description


2179 Ramucirumab Concentrate for Solution for lnfusionEach vial contains Ramucirumab 500mg I 50ml vial component :Ramucirumab SOOmgL-Histidine 32.5mgl-Histidine Monohydrochloride 61.0mg Glycine 499mgSodium Chloride 219mgPolysorb~te ·80 S.Omg Water for Injection q.s .

Ell LILLY AND COMPANY (INDIA) PVTLTD

114100/50ml vial

. 50mlv•al FI~ST

I Packing


SOmlvial

CVRAMZA 500MG Mfg: Lilly, S.A., Spain

SAME AS IN ITEM

Rupees one lac fourteen thousand one hundred only

2180 Each 1 ml conatins: Secukinumab 150mg Sucrose 92.43mg L-Histidine I L- Histidine HCL Monohydrate 4.656 mg Polysorbate 80- 0.60mg.

Sandoz Pvt. Ltd. 12857/1 vial 1 vial FIRST

1 vial

Scapha Mfg: Novartis Pharma Stein AG, switzerland SAME AS IN ITEM

Rupees twelve thousand eight hundred fifty seven only

2181 Golimumab (r-DNA origin) Each single use Pre-Filled Syringe contians : Golimumab SOmgiO.Sml Component [amount per dose (mg)]: Gollmumab (CNTO 148) -50mg, Sorbitol -20Smg, L-Histidine -0.44mg, Polysorbate 80 • 0.075mg Water for Injection - O.Smg


42135.47/1 PFS PFS of O.Sml FIRST

1 PFS

SIMPONI 1X50MG AUTOINJ. Mfg: Baxter Pharmaceutical Solutions, USA SAME AS IN ITEM

Rupees forty two thousand one hundred thirty five paisa forty seven only

Page 17 of23






490 MYCOPHENOLATE MOFETIL TAB - Each tab to contain: 1 tab Mycophenolate Mofetil 500mg.


LTD

Panacea Biotec Ltd.

RPG LIFE SCIENCES

LTD

9.98/1 tab 10 tab FIRST MYCOFIT-500

SAME AS IN ITEM

Rupees nine paisa ninety eight only

10.2/1 tab 10 tab SECOND Mycept 500 SAME AS IN ITEM

Rupees ten paisa twenty only

10.35/1 tab 10tab THIRD Mofetyl SOOmg

SAME AS IN ITEM

Rupees ten paisa thirty five only

11708 I TACROLIMUS OINT- Each tube to contain: Tacrolimus 0.03%: l10gm GLEN MARK PHARMACEUTICALS LIMITED

WALlACE

PHARMACEUTICALS PVTLlD

42.77/lOgm 10gm tube FIRST lACROZ OINT 10GM

SAME AS IN ITEM

Rupees forty two paisa seventy seven only

67.4/10gm lOgmTube SECOND T-TOP 0.3% Oint

SAME AS IN ITEM

Rupees sixty seven paisa forty only

Page 18 of23






11709 I TACROLIMUS OINT- Each tube to contain: Tacrolimus 0.1% lwgm

GLENMARK 87/10gm 10gm tube FIRST TACROZ FORTE OINT

PHARMACEUTICALS

LIMITED

WALLACE

PHARMACEUTICALS

PVT LTD

SAME AS IN ITEM

Rupees eighty seven only

124.1/lOgm lOgmTube SECOND T-TOP FORTE Oint

SAME AS IN ITEM

Rupees one hundred twenty four paisa ten only

1970 MYCOPHENOLATE TAB - Each tab to contain: Mycophenolic 1 tab acid (as Sodium salt) 360mg

I NT AS PHARMACEUTICALS LTD

RPG LIFE SCIENCES

LTD

EMCURE

PHARMACEUTICALS

LIMITED

10.9/1 tab 10 tab FIRST MYCOFIT-S 360

SAME AS IN ITEM

Rupees ten paisa ninety only

14/1 tab 10tab SECOND Mofetyl S 360mg

Rupees fourteen only

14.04/1 tab 10 tab THIRD

Rupees fourteen paisa four only

Page 19 of23

SAME AS IN ITEM

MOFILET- S 360

{Gastro Resistant)

SAME AS IN ITEM


Rate Schedule of Running Rate Contract No. U-25/1.2/142/2017-Med V FOR RC 144




1988 TACROLIMUS TAB/CAP Each tab/cap to contain: 1 tab/cap TacrolimusO.Smg

Panacea Biotec Ltd. 8.5/1 tab/cap 10cap FIRST

Rupees eight paisa fifty only

Pangraf 0.5 SAME AS IN ITEM

RPG LIFE SCIENCES LTD

8.75/1 tab/cap 10 cap SECOND lmunotac 0.5mg

Rupees eight paisa seventy five only

11969 T MYCOPHENOLATE TAB - Each tab to contain: Mycophenolic

acid (as Sodium salt) 180mg

Panacea Biotec ltd. 29.9/1 tab 10 tab FIRST

Rupees twenty nine paisa ninety only

1

1971 I MYCOPHENOLATE TAB - Each tab to contain: Mycophenolic acid (as Sodium salt) 540mg

Panacea Biotec Ltd. 88/1 tab 10 tab FIRST

Rupees eighty eight only

r 2183 1 Heparin Topical Solution 1000 IU/ml Each ml contains Heparin Sodium IP 1000 IU Absolute AlcohoiiP 10% V/V

TROIKAA PHARMACEUTICALS LIMITED

82.14/Sml 5 ml Glass FIRST Bottle

Rupees eighty two paisa fourteen only

Page 20 of23

SAME AS IN ITEM

1 tab

MyceptS 180 SAME AS IN ITEM

1 tab

MyceptS540 SAME AS IN ITEM

Sml

PHLEBOTROY QPS

SAME AS IN ITEM




[Item No I Drug Description


1990 SEVE LAMER SACHET - Each sachet to contain:Sevelamer Carbonate 800 mg

Sanof1 Synthelabo {I) 32.86/1 sachet Pack of 90 FIRST Pvt. Ltd. Sachets .

Rupees thirty two paisa eighty six only

1455a LOW CALCIUM CAPD - Each to contain: CAPD Bags with 1.5% concentration containing 40 mEq/litre of lactate and 2.5 mEq/litre of Ca with asymmetrical Y connector

Baxter {lnd1a) Pvt. Ltd.

176/2Ltr Bag 2Ltr Bag FIRST

Rupees one hundred seventy six only

I Packing


1 sachet

Renvela Mfg: Genzyme Ireland Ltd., Ireland SAME AS IN ITEM

2Ltr Bag

OIANEAL PO 2 Mfg: Baxter Healthcare Philipines Inc. Philippines SAME AS IN ITEM

,---,-----.----:-----c-----:--~---:------------------,,--------~ ~-------

1455b LOW CALCIUM CAPD- Each to contain: CAPD Bags with 2.5% 2Ltr Bag concentration containing 4-0 mEq/litre of lactate and 2.5 mEq/litre of Ca with asymmetrical Y connector

Baxter {India) Pvt. 176/2Ltr Bag 2Ltr Bag FIRST Ltd.

Rupees one hundred seventy six only

OIANEAL PO 2 Mfg: Baxter Healthcare Phillpines Inc. Philippines SAME AS IN ITEM

1339b HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN - Each vial to 1 Vial contain: Human Tetanus Specific Immunoglobulin 500 units.

Bharat Serums and 1496.25/1 Vial Vial FIRST Tetglob 500 i.u. Vaccines Limited

SAME AS IN ITEM

Rupees one thou$and four huhdred ninety six paisa twenty five only

Page 21 of23



Valid from Thursday May 3'd 2018 to Saturday May znd 2020

[item No I Drug Description I Packing


1652b HEPATITIS B IMMUNOGLOBULIN INJ - Each 1m I to contain:lnj. 1m I vial Hepatitis B Immunoglobulin 200 IU

RELIANCE LIFE 3198/1ml vial 1m I Vial FIRST HEPAREL 2001U SCIENCES PVT LTD

SAME AS IN ITEM

Rupees three thousand one hundred ninety eight only

1814 IMMUNOGLOBULIN - Each to contain: Rho (D) Immune 1 inj Globulin (Human) 1500 IU.(300mcg)

Bharat Serums and 1937.6/1 inj Vial FIRST Rhoclone 300 meg Vaccines Limited

SAME AS IN ITEM

Rupees one thousand nine hundred thirty seven paisa sixty only

-1819 IMMUNOGLOBULIN - Each 1 ml solution contain : Active 1 vial

substance(s) Human plasma proteins so mg, lgM 6 mg (12%) , lgA 6 mg (12%) lgG 38 rng ("76%)

PAVIOUR 4809.09/1 vial 10Ml VIAL PHARMACEUTICALS PVT. LTD

FIRST PENTAGLOBIN Mfg: Biotest Pharma GmbH, Germany SAME AS IN ITEM

Rupees four thousand eight hundred nine paisa nine only

1919

IANTI RABIES VACCINE " Each ml to contain : Immunoglobulin (Human)) 1501U

Bharat Serums and 4278.4/2ml 2 ml Pre Filled Vaccines Limited amp/vial Syringe

HRG (Rabies 2m I amp/vial

FIRSt Berirab P Mfg: CSL Behring GmbH, Germany SAME AS IN ITEM

Rupees four thousand two hundred seventy eight paisa forty only

Page22 of23

J

I

I


Rate Schedule of Running Rate Contract No. U-25/12/142/2017'Med V FOR RC 144

Valid from Thursday May 3rd 2018 to Saturday May znd 2020

]Item No

Firm Name

1339a

] Drug Description

Firm Rate/ unit Firm Packing Preference

I HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN - Each vial to contain: Human Tetanus Specific Immunoglobulin 250units.

Bharat Serums and 855.75/1 Vial 1 VIal FIRST Vaccines Limited

[Packing


1 Vial

Tetglob 250 i.u.

SAME AS IN ITEM

Rupees eight hundred fifty five paisa seventy five only

2185 Meningococcal Group (A,C,Y and W135) Diphtheria Toxoid Conjugate Vaccine

Polysachharide 0.5 ml Vial

Sanofi Pasteur India 3500/0.5 ml Vial 0.5 ml Vial FIRST Menactra Mfg: Sanofi Pasteur Inc., USA SAME AS IN ITEM

Private Limited

2186

BIOLOGICAL E LIMITED

Rupees three thousand five hundred only

Snake Anti venin (Polyvalent) IP 10m! (Enzyme refined Equine Globulins) Each lml neutralises: 0.60mg of Cobra venom (Naja Naja), 0.45mg of Common Krait Venom(Bungarus Caeruleus), 0.60mg of Ruseefls Viper Venom (Vipera russelli), 0.45mg of Saw scaled Viper Venom (Echis carinatus).

259/lOml 10 MLVIAL FIRST

Rupees two hundred fifty nine only

10m I

SAME AS IN ITEM

Bharat Serums and Vaccines Limited

442.4/lOrnl 10ml SECOND Snak Venom Antiserum( Lyophilized) SAME AS IN ITEM

Rupees four hundred forty two paisa forty only

Page 23 of23

I

Documents

CENTRAL RATE CONTRACT NO. -144€¦ · E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 144 EFFECTIVE FROM 03.05.2018 TO 02.05.2020. Sir I Madam, Please find enclosed a copy of the